Treatment of glioblastoma in Greenlandic patients

References

• Bundgaard JS, Petersen AJ, Geisler UW, et al. [Clinical management of haematology in Greenland]. Ugeskr Laeger. 2022;184(29). http://www.ncbi.nlm.nih.gov/pubmed/35959818.
   Google Scholar
• Petersen JK, Scheie D, Boldt HB, et al. [Integrated diagnostics of brain tumours based on histological and molecular features]. Ugeskr Laeger. 2019;181(6). http://www.ncbi.nlm.nih.gov/pubmed/30729918.
   Google Scholar
• Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a society for Neuro-Oncology (SNO) and european society of Neuro-Oncology (EANO) consensus review on current management and future directions. In Neuro-oncology. Vol. 22. Issue 8. Oxford University Press; 2020. pp. 1073–951. doi: 10.1093/neuonc/noaa106
   Google Scholar
• Vollmann-Zwerenz A, Leidgens V, Feliciello G, et al. Tumor cell invasion in glioblastoma. In International journal of molecular sciences. Vol. 21. Issue 6. MDPI AG; 2020. doi: 10.3390/ijms21061932
   Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2019;21(2):167–178. doi: 10.1093/neuonc/noy132
   PubMed Web of Science ®Google Scholar
• Michaelsen SR, Christensen IJ, Grunnet K, et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013;13(1): doi: 10.1186/1471-2407-13-402
   PubMedGoogle Scholar
• Hegi ME, Diserens A-C, Gorlia T, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi: 10.1056/NEJMoa043331
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091. doi: 10.1200/JCO.2013.49.6968
   PubMed Web of Science ®Google Scholar
• Abedi AA, Grunnet K, Christensen IJ, et al. A prognostic model for glioblastoma patients treated with standard therapy based on a prospective cohort of consecutive non-selected patients from a single institution. Front Oncol. 2021;11:11. doi: 10.3389/fonc.2021.597587
   Web of Science ®Google Scholar
• Ostrom QT, Fahmideh MA, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. In Neuro-oncology. Vol. 21. Issue 11. Oxford University Press; 2019. pp. 1357–1375. doi: 10.1093/neuonc/noz123
   Google Scholar
• Tang X, Zuo C, Fang P, et al. Targeting glioblastoma stem cells: a review on biomarkers, Signal Pathways and targeted therapy. In Frontiers in oncologyVol. 11. Frontiers Media S.A; 2021. doi: 10.3389/fonc.2021.701291
   Google Scholar
• Nørøxe DS, Yde CW, Østrup O, et al. Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study. Mol Oncol. 2020;14(11):2727–2743. doi: 10.1002/1878-0261.12790
   PubMed Web of Science ®Google Scholar
• Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–540. doi: 10.1016/S1470-2045(19)30856-3
   PubMed Web of Science ®Google Scholar
• Wick W, Dettmer S, Berberich A, et al. N 2 M 2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019;21(1):95–105. doi: 10.1093/neuonc/noy161
   PubMed Web of Science ®Google Scholar
• Fougner V, Hasselbalch B, Urup T, et al. RTID-04. gliotarget: a danish nationwide phase i/ii platform trial focusing on individualized targeted treatment for newly diagnosed glioblastoma patients based on genomic profiling. Neuro Oncol. 2021;23(Supplement_6):vi193–vi193. doi: 10.1093/neuonc/noab196.766
   Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World health Organization classification of tumors of the Central nervous System: a summary. In Acta Neuropathologica. Vol. 131. Issue 6. Springer Verlag; 2016. pp. 803–820. doi: 10.1007/s00401-016-1545-1
   Google Scholar
• Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? In Acta Neuropathologica. Vol. 125, 2013. pp. 621–636, Issue 5, 10.1007/s00401-013-1106-9.
   Google Scholar
• Nørøxe DS, Poulsen HS, Lassen U. Hallmarks of glioblastoma: a systematic review. In ESMO Open. Vol. 1. Issue 6. BMJ Publishing Group; 2016. doi: 10.1136/esmoopen-2016-000144
   Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. doi: 10.1056/nejmoa0808710
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. In Acta Neuropathologica. Vol. 136. Issue 5. Springer Verlag; 2018. pp. 805–810. doi: 10.1007/s00401-018-1913-0
   Google Scholar
• Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020;22(4):515–523. doi: 10.1093/neuonc/noz200
   PubMed Web of Science ®Google Scholar
• Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020. In JNCCN journal of the national comprehensive cancer network. Vol. 18. Issue 11. Harborside Press; 2020. pp. 1537–1570. doi: 10.6004/JNCCN.2020.0052
   Google Scholar
• The Danish Health Authority. (2019). Pakkeforløb for primaer hjernekraeft For fagfolk. https://www.sst.dk/-/media/Udgivelser/2019/Primaer-hjernekraeft/Pakkeforloeb-for-primaer-hjernekraeft.ashx?sc_lang=da&hash=FA06B4B8109FC5F7942E147A8C25A0C3
   Google Scholar
• Region Hovedstaden Center for Sundhed. (2021). Kræftplan for Region Hovedstaden 2020/2021. https://www.regionh.dk/Sundhed/Politikker-Planer-Strategier/Documents/Kr%C3%A6ftplan-del1-2021.pdf
   Google Scholar
• NORDCAN Association of the Nordic Cancer Registries. Greenland brain and CNS excluding endocrine tumors. 2022. https://Nordcan.Iarc.Fr/En/Factsheets https://gco.iarc.fr/media/nordcan/factsheets/92/en/countries/304/brain_and_cns_excluding_endocrine_tumors-320-greenland-304.pdf
   Google Scholar
• Peqqissutsimut Pitsaaliuinermullu Aqutsisoqarfik/Styrelsen for Sundhed og Forebyggelse. (n.d.-a). Danmarkimi suliarineqarnissat ingerlanneqassappat Når din behandling foregår i Danmark. Retrieved July 20, 2022, from https://peqqik.gl/-/media/Files/Patientinfo/BrochureJS.pdf?la=da-DK
   Google Scholar
• Buszek SM, Al Feghali KA, Elhalawani H, et al. Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the national cancer database. Sci Rep. 2020;10(1). doi: 10.1038/s41598-020-61701-z
   PubMed Web of Science ®Google Scholar
• Peqqissutsimut Pitsaaliuinermullu Aqutsisoqarfik/Styrelsen for Sundhed og Forebyggelse. (n.d.-b). Velkommen til Det grønlandske Patienthjem Kalaallit peqqissartut Illuat/Det grønlandske Patienthjem. Retrieved July 20, 2022, from https://peqqik.gl/-/media/Files/Patientinfo/DK-brochure-fra-RH-hjemmesidepdf.pdf?la=da-DK
   Google Scholar
• Leao DJ, Craig PG, Godoy LF, et al. Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques. In American Journal of Neuroradiology. Vol. 41. Issue 1. American Society of Neuroradiology; 2020. pp. 10–20. doi: 10.3174/ajnr.A6358
   Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. Vol. 28. Issue 11. p. 1963–1972; 2010. doi: 10.1200/JCO.2009.26.3541
   Google Scholar
• Kristiansen MF, Mikkelsen RM, Kristiansdóttir T, et al. Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries. Int J Cancer. 2023;152(10):2090–2098. doi: 10.1002/ijc.34456
   PubMed Web of Science ®Google Scholar